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SUMMARY
Potential disease-modifying therapies for neurodegenerative disorders need to be introduced prior to the 
symptomatic stage in order to be effective. However, current diagnosis of neurological disorders mostly 
rely on measurements of clinical symptoms and thus only identify symptomatic subjects in their late 
disease course. Thus, it is of interest to select and integrate biomarkers that may reflect early disease-
related pathological changes for earlier diagnosis and recruiting pre-sypmtomatic subjects in a 
prevention clinical trial. Two sources of biological information are relevant to the construction of 
biomarker signatures for time to disease onset that is subject to right censoring. First, biomarkers’ 
effects on disease onset may vary with a subject’s baseline disease stage indicated by a particular 
marker. Second, biomarkers may be connected through networks, and their effects on disease may be 
informed by this network structure. To leverage these information, we propose a varying-coefficient 
hazards model to induce double smoothness over the dimension of the disease stage and over the space 
of network-structured biomarkers. The distinctive feature of the model is a non-parametric effect that 
captures non-linear change according to the disease stage and similarity among the effects of linked 
biomarkers. For estimation and feature selection, we use kernel smoothing of a regularized local partial 
likelihood and derive an efficient algorithm. Numeric simulations demonstrate significant improvements 
over existing methods in performance and computational efficiency. Finally, the methods are applied to 
our motivating study, a recently completed study of Huntington’s disease (HD), where structural brain 
imaging measures are used to inform age-at-onset of HD and assist clinical trial design. The analysis 
offers new insights on the structural network signatures for premanifest HD subjects.
Keywords: Clinical trial design; Large-scale biomarkers; Locally varying effect; Network regularization; Neurological 
disorders.
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1. INTRODUCTION
It has been recognized in the neurological disorders research community that potential disease-modifying
therapies will need to be introduced prior to the symptomatic stage. However, current diagnosis of neuro-
logical disorders rely on measurements of clinical symptoms and thus only identify symptomatic subjects.
To assist in earlier diagnosis and ultimately early intervention, recent efforts have focused on revising cur-
rent diagnostic criteria to incorporate objective biomarkers and subtle clinical signs that appear early in
the disease process (Biglan and others, 2013). Early diagnosis may have acceptable sensitivity but low
specificity when measured against current “gold standards” for clinical diagnosis. Thus, it is important
to integrate the complementary contribution of biomarkers and estimate their effect profiles on time to
disease diagnosis in order to improve accuracy. Furthermore, large-scale biomarkers (e.g., genomic and
neuroimaging measures) are increasingly explored to assist clinical trial recruitment (Hua and others,
2016), which also calls for constructing biomarker signatures informative of a clinical trial endpoint (e.g.,
time-to-diagnosis).
Although Cox proportional hazards regression model has been used widely for time-to-event outcomes,
it does not capture several real-world complexities. First, for many neurodegenerative disorders, biomarker
effects may vary with age or diseases stage. For example, for Huntington’s disease (HD), the CAG-repeat-
Age Product score (CAP score, Zhang and others, 2011) is commonly used as an index summary marker
for disease stage. As shown in Paulsen and others (2014) using data collected from our motivating study,
PREDICT-HD, the changes in regional brain volumetric biomarkers, which are strongly associated with
HD diagnosis, manifest different rates of decline for subjects at distinct disease stages represented by their
CAP scores. The change in various markers as a function of CAP score is often non-linear (e.g., Figure 4
in Ross and others, 2014). See also our preliminary study in Section 2. As another example, research on
neurobiological processes that underlie complex social and emotional behaviors reveals an age-dependent
effect pattern for neuroimaging biomarkers. Hence, in order to accurately inform disease onset using these
biomarkers, it is crucial to recognize and model their varying effects for subjects at a different disease
stage or age.
Second, a large number of genomic and neuroimaging biomarkers are often collected, and biological
studies may reveal meaningful network structures of the underlying relationship among the biomarkers.
The motivating example for this work is the structural covariation network of brain (Chen and others,
2008; Eidelberg and others, 2011), which sheds lights on the patterns of structural changes in human brain.
For such networks, the mean cortical thickness or other structural volumetric measures over each region of
interest (ROI) are taken as the nodal value at the anatomical locations defined by theAutomaticAnatomical
Labeling atlas (Tzourio-Mazoyer and others, 2002) or the cortical atlas (Desikan and others, 2006). The
network is estimated from association matrix of nodal values, and weighted edges are obtained from entries
in the matrix, and unweighted and undirected edges are defined by thresholding the correlation matrix.
Another example is the gene expression transcriptional network (Zhang and Horvath, 2005) characterized
by co-expression of genes. When biomarkers are involved in the same biological process and thus affect
diseases or phenotypes through some common biological mechanism or pathways, their effects manifested
on disease outcome are expected to be correlated (Li and Li, 2010; Alexander-Bloch and others, 2013).
Gene expressions and neuroimaging biomarkers often exhibit comparable effect trajectories due to their
similar involvement in function (Zhang and others, 2013) or spatial proximity (Cuingnet and others,
2013).
This article aims to propose an efficient method to account for the aforementioned biologically relevant
information when constructing biomarker signatures for time to disease onset. Incorporating multi-
dimensional and network-structured biomarkers with local varying-effects poses complicated challenges
on the analysis of time-to-event data. Existing methods can only handle some of the challenges but not all.
To deal with large number of covariates for time-to-event outcomes, many penalized estimation methods
have been developed in recent years under linear model, non-linear model, and Cox model framework.
See for example, Li and Liang (2008) for varying-coefficient models, Li and Li (2010) and Huang and
others (2011) for linear regression, and Engler and Li (2009), Liu and Zeng (2013) for censored data.
Other related work includes Zhang and others (2013) and Sun and others (2014) which assumes a con-
stant vector of parameters and introduce Laplacian penalty to Cox model. None of the existing work can
simultaneously accommodate moderate to large number of non-parametric varying-coefficient functions
for predicting disease onset with network-structured biomarkers.
In this work, we adopt a local proportional hazards model framework for time-to-event outcomes
to estimate biomarker profiles non-parametrically. There are two parallel smoothing procedures serving
distinct goals. First, to reflect the underlying biology that subjects at a similar disease stage may share
similar biomarker profile, biomarker effects are smoothed along the dimension of disease stage to achieve
interpretable results matching the biological process. For this purpose, local kernel smoothing is used
to borrow information across subjects with comparable disease stages. The second smoothing procedure
assumes that the biomarkers linked in a network express correlated effects on the outcome, and hence
their profiles are smoothed across the network links to borrow information from connected nodes. For
this purpose and to incorporate large-scale biomarkers while achieving desirable sparseness, Laplacian
penalty and L1 penalty are implemented in the estimation. We develop a fast coordinate descent algorithm
based on quadratic approximation at each local value of the disease stage. Additionally, we provide a
data-driven approach to select tuning parameters with superior empirical performance.
The rest of this article is organized as follows. In the next section, we present the motivating study,
PREDICT-HD (Paulsen and others, 2014), and some preliminary analyses. In Section 3, we describe
a varying-coefficient network-regularized method under a local Cox proportional hazards model, a fast
coordinate descent algorithm for implementation, and an effective procedure for the bandwidth selection.
In Section 4, we show through simulation studies that our method significantly outperforms existing non-
local approaches and demonstrate that our bandwidth selection procedure provides a tuning parameter close
to the optimal value. In Section 5, we apply our methods to the motivating study, PREDICT-HD, where the
whole brain structural magnetic resonance imaging (MRI) data are used to estimate a network-regularized
biomarker signature for the age-at-onset of HD. The analysis results further reveal the differential effects
of imaging biomarkers depending on a subject’s baseline disease stage. Finally, we conclude the article
with some discussions in Section 6.
2. PRELIMINARY ANALYSES OF THE MOTIVATING STUDY DATA
There is an increasing body of literature suggesting that brain networks measured by neuroimaging
biomarkers play important roles in the neurodegenerative process. For example, Chen and others (2008)
demonstrated existence of topological patterns of cortical networks. Eidelberg and others (2011) described
various kinds of brain networks in HD, and Feigin and others (2007) suggested thalamic metabolic spa-
tial covariance is associated with age-at-onset of HD. Novak and others (2012) showed that structural
connectivity-based topography of the basal ganglia is altered in premanifest and early manifest HD sub-
jects. Furthermore, Alexander-Bloch and others (2013) suggested structural and functional connectivity
are likely to be related, and thus the effects of connected nodes manifested on the clinical outcome may be
similar. Incorporating such similarity over network structure in the analyses may offer greater accuracy
to predict disease onset.
Another important empirical observation made in HD research (Zhang and others, 2011; Paulsen
and others, 2014; Ross and others, 2014) is that the trajectories and effects of imaging and clinical
biomarkers on the onset of HD may vary according to a widely used summary index of baseline disease
stage/disease burden, referred as the CAPs score (Zhang and others, 2011, details in Section 5). Thus, this
CAPs-dependent effect on HD onset can be captured by using CAPs as the index of a varying-coefficient.
Our goal is to incorporate the baseline network structure and the prior evidence of local CAP-dependent
effects to reflect the underlying biology and gain stability and efficiency for predicting age-at-onset of HD,
especially in applications with large-scale data. We consider structural covariation network constructed
from high-resolution structural MRI measures collected from healthy controls in the newly completed
PREDICT-HD study (Paulsen and others, 2014). Baseline structural MRI measures were preprocessed
(Paulsen and others, 2014) using Freesurfer 5.2 (http://surfer.nmr.mgh.harvard.edu), which provided delin-
eation of cortical and subcortical ROIs. The covariation network structure is constructed based on the
association (correlation) matrix of subcortical volumetric measures (Bullmore and Bassett, 2011).
To empirically illustrate the two main biological and clinical features of HD research (structural net-
work and CAPs-dependent effect), Figure A1(a) (Online supplementary material available at Biostatistics
online) presents the structural covariation network estimated from the PREDICT-HD data. The structural
covariation network shows that the left and right side ROIs of the same region are highly associated
especially for Thalamus, Putamen, Amygdala, and Caudate regions. Using Thalamus ROI as an exam-
ple, we fitted a non-parametric varying-effect hazard function model with age-at-onset of HD as outcome.
FigureA1(b) (Online supplementary material available at Biostatistics online) shows that the effect profiles
of these two highly linked ROIs (ρ = 0.92) are largely similar and vary with CAPs.
In the remaining sections, we will propose methodology to construct network-informed (based on
Figure A1(a) Online supplementary material available at Biostatistics online) local biomarker profiles to
capture the changes according to CAPs for all ROIs. Specifically, we will incorporate the profile similarity
over structural covariation network as observed in Figure A1(a) (Online supplementary material available
at Biostatistics online) and the varying effect along the dimension of CAPs as observed in Figure A1(b)
(Online supplementary material available at Biostatistics online). We expect that incorporating these two
main biological features will improve the predictive performance for predicting HD onset in the presence
of multi-dimensional neuroimaging biomarkers. We will also demonstrate the utilities of biomarker sig-
natures to improve the clinical trial design efficiency. In addition, separating disease stage index CAPs
from other biomarkers in the network effectively accounts for their interactions. At the same time, the
network structure among other biomarkers is preserved across all disease stages. To retain maximum flex-
ibility, we do not assume any parametric form of the effect profiles. When a simpler functional form fits
data adequately, our data-driven methodology will capitalize on this information to improve estimation
efficiency.
3. METHODOLOGY FOR NETWORK-REGULARIZED VARYING COEFFICIENT HAZARDS MODEL
Let Ti be the time-to-event of interest (e.g., age-at-onset of a disease) and Ci be the censoring time for
the ith subject. Denote by T̃i = min(Ti, Ci) the observed event time or censoring time and denote by
δi = I (Ti ≤ Ci) the event indicator, where I (·) is an indicator function. Let X i = (Xi1, · · · , Xip)T denote a
vector of biomarkers and let Wi denote the index marker for the disease stage (e.g., CAPs score representing
the baseline disease stage for HD) which is treated separately from X i. We assume that given X i and Wi,
the censoring time is independent of event time, and observations collected on different subjects are
independent. To capture the local effect from biomarkers that change with W , we consider a varying-
coefficient Cox model, where the key interest is to estimate a vector of w-dependent functions (biomarker
effect profiles as network-regularized signatures for disease onset), and a w-dependent baseline hazard
function. Specifically, the hazard function takes the form





where λ0(t, Wi) is an unspecified baseline hazard and β(w0) is a vector of local effects at W = w0.
Our methodology involves two parallel smoothing procedures. First, to borrow information from sub-
jects with similar values of w to estimate β(·) non-parametrically, we employ local kernel smoothing by
incorporating a symmetric kernel function Khn(·) (Fan and others, 2006), where hn is a data-dependent





























Second, to incorporate network structure exhibited among components of X at each local point of w0,
the smoothness of β(w0) over the network graph is induced by including a Laplacian penalty to the local
likelihood. Specifically, since the biomarkers connected by an edge in the network express similar effects
due to, for example, their similar involvement in structural or functional brain networks (Alexander-
Bloch and others, 2013), or sharing genetic pathways in gene expression networks (Li and Li, 2010), we
maximize the local log-partial likelihood with a Laplacian penalty term to induce smoothness of β(w0)
across network nodes. The estimator of β(w0) is then obtained through


























where ‖ · ‖1 is the L1 norm to induce sparsity, E is the set of all edges, wkl is the given weight between




1 − vkk/dk , if k = l and dk = 0,
−vkl/
√
dkdl , if k and l are adjacent,
0, otherwise.
Node k is an isolated node if dk = 0.
Remarks. The weights vkl usually represent the strength of the link between nodes k and l. Conventionally,
anatomical connectivity, which is inferred from thresholding an association matrix, yields vkl = 1 if the
association between them is larger than a given threshold and 0 otherwise (Bullmore and Bassett, 2011).
In some situations, continuous weights vkl may be used and dk = ∑l:(k ,l)∈E vkl is adopted as a way to
measure the degree of a node without applying any threshold to the association matrix. In our motivating
example in Section 2, the network is defined by the association matrix of structural MRI measures and the
continuous weights are used. Lastly, we remark that local Lasso and Enet penalties are two special cases
of (3.3): when λ2 = 0 or L is an identity matrix, respectively.
To obtain the profile of coefficients, we solve the objective function (3.2) at a series of w0 for w0 ∈ W ,
where W could be a set of all data points, equally spaced points over a range or any user-defined points:







l(β(w0)) + p(β(w0); λ1, λ2)
)⎫⎬⎭ . (3.4)
Each β(w0) is estimated separately but with the same set of tuning parameters.Additionally, we propose an
adaptive version of the Laplacian network penalty (AlocNet). In this version, we modify the L1 penalty to
an adaptive version as in Zhang and Lu (2007) and also adjust the signs of the coefficients in the Laplacian
penalty to better handle the linked covariate with opposite signs of the effect sizes. Similar approach of
accounting for the opposite signs of parameters in a network was proposed in Kunegis and others (2010),
Zhang and others (2012), and Sun and others (2014). In our case, the local penalty term at w0 in AlocNet
is


















where β̆(w0) is an initial estimator of β. It could be obtained from a ridge regression by replacing





Key advantages of the proposed method are the induced double smoothness over the dimension of
disease stage (e.g., W ) and the nodes in the network space, the ability to incorporate their potential non-
linear interactions, and the capability to handle large number of structured biomarkers while producing a
sparse and interpretable model. With the estimated β(w0), we can estimate the baseline cumulative hazard




δiI (T̃i ≤ t)Khn(Wi − w0)∑
T̃k ≥T̃i exp{β̂(w0)T Xk}Khn(Wk − w0)
. (3.5)
We present a fast coordinate descent algorithm based on quadratic approximation at each value of the
disease stage for computation in SectionA1 of the Supplementary material available at Biostatistics online.
The details on tuning parameter selection and computational efficiency analysis are described in Sections
A2 and A3 of the Supplementary material available at Biostatistics online. We prove the theoretical oracle
property of the proposed method in Section A4 of the Supplementary material available at Biostatistics
online. The main challenge is that the non-parametric approximation bias (from local kernel smoothing)
needs to be controlled carefully at certain stochastic rates, which entails using non-parametric regression
theories and large deviation results to derive weak oracle properties for a class of network-regularized
optimization problems.
4. SIMULATION STUDIES
We conducted extensive simulations to evaluate the performance of the proposed local varying-coefficient
network method with various penalty functions for variable selection. To mimic the structural covariation
network structure, we constructed X in independent blocks/regions and the nodes within each block
were correlated with each other. We simulated the network to be consisted of 23 blocks and each block
contained five nodes: for the kth block of X (k = 1, ..., 23), we generated X k from a multivariate normal
distribution X k ∼ N (0, P), where P was a correlation matrix with ρ as off-diagonal entries. Three degrees
of correlations, ρ = 0.2, 0.5, 0.8, were considered to evaluate different strengths of network structures.
Only 15 covariates from three blocks had non-zero effects on the outcome, and the effects of the informative
biomarkers varied according to the disease stage marker, W (e.g., CAP score for predicting HD onset),
which was generated from a uniform distribution U (0, 1). The underlying hazard function for subject i was




, where λ0(t) was specified by a Weibull distribution
with shape parameter 5 and scale parameter 2. Censoring time was generated from the uniform distribution
to yield 30% censored subjects. For βj(w)’s, two different models were considered in the simulation. For
the first model, we specified the coefficients as β1(w) = · · · = β5(w) = 2 exp(−w3), β6(w) = · · · =
β10(w) = 4w(1−w), β11(w) = · · · = β15(w) = sin(πw)+ cos(πw). In the second model, we considered
the case when β(w) had the same forms as in the first model but within each block, two of the five nodes
were assigned opposite signs.
We considered the sample size n = 500. For each simulated dataset, we considered the local points
W0 = {w0} with w0 from 0.1 to 0.9 with increments of 0.1, the grid of α between 0.1 to 0.9 with increments
of 0.1, the length of searching path for λ at K = 20 and the bandwidth at h = 0.1, · · · , 0.5. Ten-fold cross-
validation was applied to choose the optimal tuning parameters and the bandwidth based on cross-validated
partial likelihood. For each model, simulations were repeated 100 times.
In all simulation studies, we reported the estimation accuracy, variable selection performance, and the
data-driven procedure to select the bandwidth. We computed integrated mean squared error (IMSE) to








We calculated the accuracy (ACC) defined as the percentage of correctly identified relevant and irrelevant
covariates, the number of incorrectly identified non-zero covariates (IN), and the number of correctly
identified non-zero covariates (CN).
Table 1 summarizes simulation results comparing the proposed local methods with existing methods
under various penalty functions (e.g., Anet, Net, Enet, Lasso). When β(w) is assumed to be constant over
the range of w (non-local methods) and using the adaptive network penalty (Anet), our method can be
reduced to the non-local methods in Zhang and others (2013) and Sun and others (2014). Table 1 shows that
the proposed localized methods (e..g., AlocNet) performed better than non-localized ones in terms of both
estimation accuracy and variable selection property due to taking advantage of the local smoothing. Within
the localized methods, we observed that AlocNet gave the smallest IMSE for both Models 1 and 2 with
different correlations among the network covariates. AlocNet substantially reduced the IMSE compared
to all alternatives (e.g., around 60% reduction compared to locNet). When the connected biomarkers have
the same signs, locNet performed better than locEnet and locLasso. For Model 2 when the signs were
different for the connected biomarkers, locNet had worse performance compared to AlocNet because the
unadjusted penalty (3.3) cannot reflect the opposite signs. LocNet performed similarly as locEnet and
better than locLasso when the correlation was medium and high.
For the variable selection performance, we calculated ACC, IN, and CN. All four local methods were
able to correctly identify both informative and null covariates except for Model 2 with high correlation
among the covariates. For Model 1, AlocNet, and locNet had similar performance and better than locEnet
and locLasso with slightly more correctly identified non-zero and less incorrectly identified non-zero
covariates. For Model 2, AlocNet had the best performance on variable selection. When the correlation
Table 1. Comparison of estimation and selection performance using proposed local methods (i.e.,
local adaptive network [AlocNet], local network [locNet], local elastic-net [locEnet], and local lasso
[locLasso]) and existing non-local methods (adaptive network [ANet], network [Net], elastic-net [Enet],
and Lasso) for Models 1 and 2 with three different network structures ρ = 0.2, 0.5, 0.8
Proposed local methods Non-local methods
AlocNet locNet locEnet locLasso ANet Net Enet Lasso
Model 1
ρ = 0.2
IMSE∗ 2.32 5.42 8.60 8.48 13.40 14.36 14.64 14.52
ACC† 1.00 1.00 1.00 1.00 0.89 0.80 0.82 0.85
IN‡ 0.00 0.00 0.02 0.02 11.38 23.35 20.96 16.74
CN§ 15.00 15.00 14.94 14.95 14.27 14.98 14.76 14.72
ρ = 0.5
IMSE 2.18 6.16 7.97 8.51 15.11 15.69 15.92 15.85
ACC 1.00 1.00 1.00 1.00 0.89 0.86 0.85 0.91
IN 0.00 0.00 0.00 0.00 10.57 15.88 16.18 9.44
CN 15.00 15.00 14.93 14.91 12.74 14.78 14.33 14.01
ρ = 0.8
IMSE 2.35 5.00 8.40 8.38 16.27 16.46 16.62 16.64
ACC 1.00 1.00 1.00 1.00 0.87 0.89 0.87 0.92
IN 0.00 0.00 0.03 0.07 10.38 12.55 13.82 6.21
CN 14.99 15.00 14.90 14.78 10.28 14.38 13.72 12.39
Model 2
ρ = 0.2
IMSE 2.52 8.22 8.16 7.80 11.06 12.82 12.82 12.70
ACC 1.00 1.00 1.00 1.00 0.89 0.76 0.76 0.77
IN 0.00 0.06 0.04 0.08 12.10 27.36 27.58 25.84
CN 15.00 14.86 14.86 14.87 14.86 14.92 14.92 14.89
ρ = 0.5
IMSE 2.28 7.93 7.47 8.22 10.03 12.01 11.99 11.88
ACC 1.00 0.99 1.00 0.99 0.88 0.75 0.74 0.76
IN 0.00 0.20 0.22 0.26 13.99 28.75 29.17 27.51
CN 14.92 14.38 14.67 13.88 14.64 14.80 14.82 14.74
ρ = 0.8
IMSE 3.17 9.94 9.09 11.29 8.79 11.12 11.11 11.08
ACC 0.99 0.97 0.97 0.96 0.83 0.72 0.72 0.74
IN 0.40 0.36 0.24 0.73 18.87 31.06 31.14 28.61
CN 14.26 11.61 11.96 11.31 14.10 13.96 13.97 13.82
∗Integrated mean square error.
†Percentage of correctly identified relevant and irrelevant covariates.
‡Number of incorrectly identified non-zero covariates.
§Number of correctly identified non-zero covariates.
is high, AlocNet outperforms all other alternatives in terms of corrected identified informative covariates.
Note that non-local methods have reasonable performance on CN, but suffers from producing non-sparse
model.
Table 2. Performance of the bandwidth selection procedure for the proposed local methods (i.e.,
local adaptive network [AlocNet], local network [locNet], local elastic-net [locEnet], and local lasso
[locLasso])
Model 1 Model 2
AlocNet locNet locEnet locLasso AlocNet locNet locEnet locLasso
ρ = 0.2 ρ = 0.2
Best∗ 0.12 0.12 0.23 0.21 0.21 0.27 0.27 0.25
Selected 0.12 0.18 0.24 0.22 0.17 0.32 0.31 0.32
ρ = 0.5 ρ = 0.5
Best 0.10 0.10 0.19 0.19 0.21 0.30 0.30 0.30
Selected 0.10 0.12 0.22 0.21 0.19 0.36 0.37 0.35
ρ = 0.8 ρ = 0.8
Best 0.10 0.11 0.14 0.12 0.26 0.34 0.34 0.34
Selected 0.10 0.11 0.19 0.19 0.22 0.34 0.35 0.30
∗Defined as the one with smallest IMSE.
Next, we investigate performance of the proposed bandwidth selection procedure. For each replication,
we obtained the estimates for h = 0.1, . . . , 0.5, and defined the “best” bandwidth as the one with the
smallest IMSE. In Table 2, we observe that the selected bandwidths based on our procedure were very
close to the “best” bandwidths, indicating satisfactory performance of our data-driven procedure.
To make the method easily accessible for routine data analysis, we have developed an R-package
“Coxnet” and implemented several techniques for efficient computation: (i) use warm starts for estimating
β(w0) along a regularization path; (ii) use one-step coordinate descent to save time in the intermediate
update steps; and (iii) use sparse data structure to save computer memory and the time to search for the
non-zero coefficients in a sparse β(w0). A running time analysis is performed for simulation setting Model
1 with various sample sizes and numbers of parameters. For each case, we set the entire solution path with
20 values and compute 9 data points in W with 10-fold cross-validation. The running time for completing
the entire solution path for all values of W and with cross-validation are summarized in the Section A3
of the Supplementary material available at Biostatistics online. From Figure A1 of the Supplementary
material available at Biostatistics online, we can see that the running time increases relatively linear with
increasing n and p.
5. APPLICATION TO PREDICT STUDY
HD is a severe neurodegenerative disorder caused by expansion of trinucleotide “C-A-G” repeats at the
HTT gene (MacDonald and others, 1993).All subjects with expanded repeats will eventually be diagnosed
with HD, but when will disease onset occur in lifetime remains unknown. We focus on the identification
of biomarkers preceding clinical diagnosis and informative of age at diagnosis to understand disease
mechanism and assist the design of neuroprotective clinical trials.
As observed in Figure ?? and suggested from the literature, the effects of HD biomarkers vary according
to disease stage or disease burden defined by the CAP score (Zhang and others, 2011). CAP score is
constructed from a centered product of “C-A-G” repeats length and age. Standardized CAP is referred
as CAPs. A Low-Med-High risk of onset classification was suggested in the literature (Zhang and others,
2011): CAPs = 0.67 (low CAPs, corresponds to unstandardized CAP = 290) and 0.85 (medium CAPs,
corresponds to unstandardized CAP = 367) for distinguishing subjects at low risk and medium risk of
onset, and CAPs = 1.00 (corresponds to CAP = 432) is another critical value, indicating high risk. We
also assessed the proportional hazard assumption by grouping subjects based on the quartiles of CAP score
W and tested the assumption in each group. The results show non-significance for all groups (P-value =
0.67, 0.86, 0.86, 0.74 for each group), which may imply the assumption is valid in our application.
We applied eight methods described in Section 4 to 840 subjects at risk of HD, who participated in
the PREDICT study and did not have HD at baseline exam. The median follow-up time was 3 years (up
to 8 years), and 128 subjects developed HD during the study. Variable W of the varying coefficient is the
baseline CAPs. The feature variables X include 8 non-imaging demographic and clinical variables [e.g.,
gender, education, baseline total motor score (TMS) from the Unified Huntington’s Disease Rating Scale
(UHDRS), and cognitive and functioning measures] and 28 subcortical MRI imaging ROI biomarkers
measured at the baseline visit. Ten-fold cross-validation was used to choose the tuning parameters and
bandwidth. All variables were standardized before model fitting.
Among the non-local methods, ANet, Net, Enet, and Lasso selected 19, 31, 30, and 24 biomarkers,
respectively. ANet had the highest C-index (Harrell and others, 1982) of 0.83 compared to Net, Enet,
and Lasso, indicating better performance, and we report some of its estimated coefficients in Table 3. As
a comparison, a regular Cox model without variable selection including all markers was fit and found
to yield a C-index of 0.84, but failed to identify several important imaging markers reported in other
literature such as Caudate and Putamen (Paulsen and others, 2014), potentially due to its inability to
handle correlated imaging biomarkers.
To be succinct, for the local methods we report the numeric estimates from AlocNet, locNet, locEnet,
locLasso at three values defining low-, medium-, and high-disease-burden group (CAPs = 0.67, 0.85, 1.00,
respectively, Section 2). Table 3 presents the biomarkers identified by AlocNet. Comparing non-local
method ANet with AlocNet, we can see that ANet misses some important biomarkers previously reported
in the literature (Paulsen and others, 2014), such as Symbol Digit Modality Test (SDMT), and does not
detect the varying effects with CAPs. The C-index for AlocNet is much higher than Anet at all three risk
groups. Most image biomarkers express greater effects for medium- and high-risk subjects as estimated the
local methods. These results suggest that imaging markers’ effects depend on the baseline disease burden,
justifying using a varying coefficient network-regularized model with CAPs as an index biomarker W .
In terms of feature selection and prediction performance, among the four local methods, Table 3 shows
that LocLasso selects the least number of biomarkers and has worse prediction performance. LocNet
and LocEnet give similar estimation and prediction performance, which is consistent with the simulation
results in the presence of opposite signs in Table 1. Compared to locNet and locEnet which do not use
the network Laplacian penalty L, AlocNet has comparable prediction performance at low CAPs but better
performance at medium and high CAPs with only slightly more biomarkers included. This comparison
illustrates the advantage of incorporating structural covariation network in prediction by AlocNet.
It may be of interest to note that some of the left and right side of brain presents asymmetric effects. For
example, only one side is identified for most of imaging biomarkers except Pallidum and Thalamus. In
addition, only right side of Pallidum shows an effect at low CAPs while the left side has effects at medium
and high score, suggesting that the right side Pallidum degeneration might be more predictive for the early
stage and the left side may be more predictive at medium and high score.Asymmetric neurodegeneration in
HD in striatal regions reported previously in Rosas and others (2001) was the right side first. However, HD
has been largely considered as a symmetric disease, the biological implication of asymmetry is unclear,
and these findings need to be confirmed in future studies.
Figure 1 graphically displays the profiles of the top 10 clinical variables and imaging biomarkers
identified byAlocNet as a function of baseline CAPs, and their 95% confidence intervals based on bootstrap
method. The two vertical dashed lines represent the thresholds for the Low-Med-High classification in





































































































































































































































































































































































































































































































































that both TMS and SDMT affect HD onset for early stage subjects (low CAPs) while the effect from TMS
persists for the medium- and high-risk stage subjects (medium and high CAPs) but the effect from SDMT
disappears. The rest “Imaging biomarkers” subfigures show that most subcortical imaging biomarkers
manifest stronger effects as the disease burden, CAPs, increases. For low risk subjects, for example with
CAPs=0.67, only Pallidum-R (volume of the right side of Palladium region) has an effect significantly
different from zero. For medium- and high-risk subjects, more biomarkers become active. These results
further demonstrate differential effects of imaging markers depending on CAPs, thus the differential
utilities to serve as risk markers to predict future disease onset. For example, Pallidum-R is useful for
early- and medium-stage subjects, and Putamen-R, Pallidum-L, Amygdala-L, Accumbens-R, Caudate-L,
Cerebellum-R, and Thalamus are useful for high risk subjects. Paulsen and others (2014) documented
various measures associated with HD progression representing imaging, motor, cognitive, functional, and
psychiatric domains. They showed different rates of decline between premanifest HD and controls using
longitudinal data and provided a ranking for several clinical and imaging biomarkers. In this analysis, we
identified similar sets of important imaging biomarkers, but with much more detailed characterization of
their effect profiles over baseline disease stage.
In Figure 2, we present the imaging networks and their effects estimated by AlocNet at CAPs =
0.67, 0.85, 1.00. Since the covariation network structure was estimated from the same underlying control
population, the estimated profiles represent the effects of ROIs on HD onset at various baseline disease
stage. For graphical demonstration purpose, a node and its edges were removed from the figure if the
node had no effect on disease onset as estimated by AlocNet. We observe that the network effects change
with CAPs. For low risk subjects with CAPs = 0.67, a highly connected network (ρ ≥ 0.7) for HD onset
is identified between Thalamus and Pallidum, similar to Feigin and others (2007). The topology of one
network signature including Thalamus, Caudate, Pallidum, and Putamen remains the same for medium
and high risk subjects, but with different effect size (radius of nodes). As CAPs increases from 0.85 to 1.00,
the effect sizes of both Thalamus-R and Putamen-R increase which may be due to the strong connection
between them, while the effect sizes of Caudate-L and Thalamus-L decreases. Note that Thalamus and
Putamen regions were also identified as structural covariance patterns by Feigin and others (2007) in a
principal component analysis using positron emission tomography imaging measures.
Lastly, we illustrate the clinical significance of our approach through using the AlocNet-identified
biomarker signatures to design a hypothetical neuroprotective prevention clinical trial with time-to-HD
diagnosis as the endpoint. We compare a targeted recruitment scheme that enriches the sample by including
subjects with a positive biomarker signature at the baseline (e.g., risk score βT (w)X greater than the
median of the population risk scores). The probability of receiving a HD diagnosis within next 5 years for
a premanifest subject with HTT gene mutation (expanded “C-A-G” repeats, Section 2) was estimated using
β̂(w) and ̂(t, w) fitted by AlocNet. Since PREDICT-HD was a natural history study where no subject had
received an active intervention, these estimates provide design parameters for the placebo arm in a clinical
trial. Figure S.2 of the Supplementary material available at Biostatistics online shows the required sample
size as a function of a range of given effect sizes (assumed hazard ratio of the intervention). The targeted
recruitment strategy substantially reduces required sample size, for example, from more than 17 000 to
close to 3000 in low risk group assuming a hazard ratio of 0.8 of the intervention (i.e., a 20% reduction in
hazard in the intervention group compared to the placebo group), and from about 5000 to less than 3000
for high risk subjects. The improvement is greater for smaller effect sizes and low risk group.
In summary, differential smooth effects of imaging ROI networks depending on CAPs are observed in
our analyses. The network signature for low risk subjects involves regions for core motor control informa-
tion hub (e.g., Thalamus, Pallidum), while additional regions for fine motor control and coordination (e.g.,
Putamen) and reward system (e.g., Amygdala, Accumbens) become active for medium and high risk sub-
jects. The medium- and high-risk networks share similar topological structure but with different effects.
Recruiting subjects with a positive biomarker signature substantially improves clinical trial efficiency.









































































































Fig. 1. Estimated effect profiles of the top 10 biomarkers (2 clinical markers and 8 imaging ROI markers) on the
hazard of HD identified by the proposed local adaptive network [AlocNet] as a function of disease stage CAPs. Shaded
area indicates pointwise 95% confidence interval. Two vertical lines divide early, moderate, and late stage based on
CAPs. Few markers have an effect at the early stage, while more markers manifest an effect at the medium or late
disease stage.
Fig. 2. Subcortical network signatures for age-at-onset of HD using PREDICT baseline imaging data estimated by
local adaptive network [AlocNet]. Node radius indicating standardized effect of a node on HD onset.
6. DISCUSSION
In this work, we propose a method to estimate locally varying biomarker network signature for disease
age-at-onset. Our method can handle large-scale structured biomarkers without imposing a parametric
form of varying-effect profiles, and thus cover both linear and potentially non-linear interactions between
network biomarkers and the disease stage biomarker. The procedure also effectively selects important
biomarkers with opposite signs due to incorporating sign information in the Laplacian penalty matrix.
The real data application reveals insights on CAPs-dependent structural MRI network signatures for HD
onset.
A simpler alternative to our method is to binning data by disease stage and then fitting a separate model
for each bin, which would provide a crude estimate of the effect profiles β(w) at certain bins of w. In fact,
this is equivalent to fitting a piece-wise constant function of effect profiles. However, such a method would
bear large bias and does not produce smooth functions β(w). Using a higher order kernel as compared to
lower order kernel (binning) will improve optimal rate if the true underlying effect function is smooth.
For linear regression, Huang and others (2011) showed that incorporating Laplacian penalty reduces
variance without incurring any bias on the estimator. Since locally around the true parameters, our objective
function is approximated by a quadratic function, similar results may hold for our method. In practice,
when there is a lack of biological knowledge to suggest effectiveness of a Laplacian prior, it can be
checked by fitting a model without such penalty and examining the resulting biomarker profiles. Similar
profiles for highly linked variables suggest that incorporating a Laplacian prior is sensible for improving
prediction of outcomes and reducing overfitting with multi-dimensional biomarkers. As shown in Figure
??, when fitting the model without Laplacian penalty using PREDICT data, the effects of left and right
side of Thalamus (ρ = 0.92) are largely similar. Furthermore, the tuning parameter associated with the
Laplacian prior is selected in a data-adaptive fashion; therefore, a large tuning parameter (smaller α) value
will indicate the usefulness of the Laplacian prior for accounting the network. Particularly, in our data
application, this tuning parameter is α = 0.1.
In our application, structural covariation network was used in the Laplacian penalty. In other appli-
cations, networks based on partial correlation that adjusts for confounding by other biomarkers can be
used when deemed appropriate. Another extension to consider is to obtain a localized network structure.
Subjects in different disease stages at the baseline exam (e.g., with different CAP scores, w0) may exhibit
distinct network patterns. It is straightforward to incorporate local network structure in our procedure
by re-defining penalty function to be dependent on the disease stage CAP score w0: β
T (w0)L(w0)β(w0),
where L(w0) is the local Laplacian matrix. Incorporating spatial correlation to estimate spatial–temporal
covariance network is also of interest, and some latent graph models may be explored.
Here, we did not study causal network such as gene regulatory network (Kanehisa and Goto, 2000),
where causal pathways and directions between genes may be known. In these cases, using a directed
acyclic graph to characterize network may be more appropriate than a Laplacian prior. However, in the
case of HD, since the HTT gene is dominant, while there may be other genes that modify age-at-onset,
they are very rare and effects may be modest (Lee and others, 2015). We assumed the network structure is
available from external sources or healthy control population.A challenging next step would be to estimate
network structure from data and incorporate estimation uncertainty in the inference for the biomarker
profiles. Lastly, when longitudinal measurements on biomarkers are available, change of network may be
considered to predict clinical outcomes.
7. SOFTWARE AND DATA
We provide an efficient R implementation of our algorithms in the R-package “Coxnet” available at GitHub
(https://github.com/yuanjiawang/Coxnet) and CRAN (https://cran.r-project.org/web/packages/Coxnet/
index.html). Data analyzed in Section 5 are publicly available through dbGaP (http://www.ncbi.nlm.nih.
gov/projects/gap/cgi-bin/study.cgi?study_id=phs000222.v3.p2).
SUPPLEMENTARY MATERIAL
Supplementary material is available at http://biostatistics.oxfordjournals.org.
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